CG Oncology GAAP EPS of -$0.90 (CGON:NASDAQ)
· seekingalpha.com
CG Oncology (CGON) Q2 earnings: GAAP EPS -$0.90, $1.0B cash runway through 2029, R&D and G&A spend rising on trials and headcount.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...